In the latest trading session, Pfizer (PFE - Free Report) closed at $42.74, marking a -0.23% move from the previous day. This change lagged the S&P 500's daily gain of 0.21%. Meanwhile, the Dow gained 0.64%, and the Nasdaq, a tech-heavy index, lost 0.05%.
Prior to today's trading, shares of the drugmaker had gained 2.34% over the past month. This has outpaced the Medical sector's loss of 0.07% and lagged the S&P 500's gain of 2.57% in that time.
PFE will be looking to display strength as it nears its next earnings release, which is expected to be April 30, 2019. In that report, analysts expect PFE to post earnings of $0.78 per share. This would mark year-over-year growth of 1.3%. Our most recent consensus estimate is calling for quarterly revenue of $12.86 billion, down 0.32% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $2.86 per share and revenue of $52.90 billion. These totals would mark changes of -4.67% and -1.38%, respectively, from last year.
It is also important to note the recent changes to analyst estimates for PFE. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. PFE is currently a Zacks Rank #3 (Hold).
In terms of valuation, PFE is currently trading at a Forward P/E ratio of 14.96. For comparison, its industry has an average Forward P/E of 15.48, which means PFE is trading at a discount to the group.
Meanwhile, PFE's PEG ratio is currently 2.57. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Large Cap Pharmaceuticals was holding an average PEG ratio of 2.14 at yesterday's closing price.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 52, which puts it in the top 21% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.